These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2563434)

  • 1. Uncoated versus coated 5-aminosalicylic acid in Crohn's disease.
    Bossi A; Giuliani GE; Del Poggio P; Fenili D; Ragaini S
    Lancet; 1989 Feb; 1(8632):276. PubMed ID: 2563434
    [No Abstract]   [Full Text] [Related]  

  • 2. Oral 4-aminosalicylic acid versus 5-aminosalicylic acid slow release tablets. Double blind, controlled pilot study in the maintenance treatment of Crohn's ileocolitis.
    Schreiber S; Howaldt S; Raedler A
    Gut; 1994 Aug; 35(8):1081-5. PubMed ID: 7926910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of an enteric-coated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease.
    Hardy JG; Healey JN; Reynolds JR
    Aliment Pharmacol Ther; 1987 Aug; 1(4):273-80. PubMed ID: 2979672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn's disease. International Mesalazine Study Group.
    Aliment Pharmacol Ther; 1990 Feb; 4(1):55-64. PubMed ID: 2104074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experience with Eudragit-S-coated mesalamine (Asacol) in inflammatory bowel disease. An open study.
    Faber SM; Korelitz BI
    J Clin Gastroenterol; 1993 Oct; 17(3):213-8. PubMed ID: 8228082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Crohn's disease with peroral 5-aminosalicylic acid.
    Rasmussen SN; Binder V; Maier K; Bondesen S; Fischer C; Klotz U; Hansen SH; Hvidberg EF
    Gastroenterology; 1983 Dec; 85(6):1350-3. PubMed ID: 6354827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioavailability of single and multiple doses of enteric-coated mesalamine and sulphasalazine.
    Corey AE; Rose GM; Conklin JD
    J Int Med Res; 1990; 18(6):441-53. PubMed ID: 1981363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet in patients with Crohn's disease or ulcerative colitis and in healthy volunteers.
    Norlander B; Gotthard R; Ström M
    Aliment Pharmacol Ther; 1990 Oct; 4(5):497-505. PubMed ID: 2129637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pericardial effusion during treatment with 5-aminosalicylic acid in a patient with Crohn's disease.
    Jenss H; Becker EW; Weber P
    Am J Gastroenterol; 1990 Mar; 85(3):332-3. PubMed ID: 2309693
    [No Abstract]   [Full Text] [Related]  

  • 10. A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Biopharmaceutic and clinical pharmacokinetic characteristics.
    Klotz U; Maier KE; Fischer C; Bauer KH
    Arzneimittelforschung; 1985; 35(3):636-9. PubMed ID: 4039590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of 5-aminosalicylic acid in inflammatory bowel disease for patients intolerant or allergic to sulphasalazine.
    Donald IP; Wilkinson SP
    Postgrad Med J; 1985 Dec; 61(722):1047-8. PubMed ID: 2869480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term management of Crohn's disease with mesalamine capsules (Pentasa). Pentasa Crohn's Disease Compassionate Use Study Group.
    Hanauer SB; Krawitt EL; Robinson M; Rick GG; Safdi MA
    Am J Gastroenterol; 1993 Sep; 88(9):1343-51. PubMed ID: 8362827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute pancreatitis during oral 5-aminosalicylic acid therapy.
    Fiorentini MT; Fracchia M; Galatola G; Barlotta A; de la Pierre M
    Dig Dis Sci; 1990 Sep; 35(9):1180-2. PubMed ID: 2390934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease.
    Prantera C; Pallone F; Brunetti G; Cottone M; Miglioli M;
    Gastroenterology; 1992 Aug; 103(2):363-8. PubMed ID: 1634054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Crohn's disease with 5-ASA.
    Katz J
    Am J Gastroenterol; 1993 Sep; 88(9):1315-7. PubMed ID: 8362823
    [No Abstract]   [Full Text] [Related]  

  • 16. [Hypersensitivity to 5-aminosalicylic acid. Value of desensitization by oral route].
    Lachaux A; Le Gall C; Loras-Duclaux I; Aboufadel A; Hermier M
    Arch Pediatr; 1997 Feb; 4(2):144-6. PubMed ID: 9097825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current salazosulfapyridine derivatives in the treatment of Crohn's disease].
    Belaiche J; Delwaide J; Louis E; Gast P
    Rev Med Liege; 1991 Jan; 46(1):16-22. PubMed ID: 2011676
    [No Abstract]   [Full Text] [Related]  

  • 18. Sulfasalazine, 5-ASA and acute pancreatitis in crohn's disease.
    Debongnie JC; Dekoninck X
    J Clin Gastroenterol; 1994 Dec; 19(4):348-9. PubMed ID: 7876525
    [No Abstract]   [Full Text] [Related]  

  • 19. [Pancreatitis associated with 5-aminosalicylic acid].
    Eckardt VF; Kanzler G; Rieder H; Ewe K
    Dtsch Med Wochenschr; 1991 Apr; 116(14):540-2. PubMed ID: 1707359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute pancreatitis in Crohn's disease due to 5-ASA therapy.
    Radke M; Bartolomaeus G; Müller M; Richter I
    J Pediatr Gastroenterol Nutr; 1993 Apr; 16(3):337-9. PubMed ID: 8492268
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.